Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)
Status:
Completed
Trial end date:
2016-03-24
Target enrollment:
Participant gender:
Summary
The study is designed to evaluate the efficacy and safety of each dose of SHP465 (12.5 and
37.5 mg) given to participants daily in the morning compared to placebo in the treatment of
adults aged 18 to 55 years diagnosed with ADHD.